New Anti-Cancer Drug Combinations: CASY Growth Inhibition Assays

A new application report describes how the CASY is successfully used in Tübingen, Germany to test new polychemotherapy regimens with growth inhibition assays. Aim of the studies * was, to generate new and more effective chemotherapy regimens.
The CASY was utilized to evaluate the growth inhibition of the regimens in cell culture quickly, simple and reliable.

Dr. J. Weinreich, Experimental Oncology, Universitätsklinikum Tübingen:
"Cytotoxicity assay using CASY enable us to perform fast, simple and reliable assessment of anti-cancer drug regimens and the subsequent chemosensitivity of carcinoma cell lines. A major advantage of CASY is that debris and dead cells can be masked in the analysis by a simple cell line specific setup and only viable cells and their aggregates are considered. However, as a complete cell status is recorded, also dead cells and debris data are available at any time.”

Read the Application report. And here find the original publication.

 

 

 

Growth Inhibition Assay with CASY: MKN-45 cells were treated with the chemotherapy cocktail EC D-D:
Red: E =. 0,37; C = 0.45; D-D = 0.41 μmol/L
Pink: E =. 0,15; C = 0.18; D-D = 0.16 μmol/L
Blue: E =. 0,075; C = 0.09; D-D = 0.082 μmol/L
Yellow: PBS control
EC D-D: epirubicin (E) + cisplatin (C) + novel duplex drug (D-D)

 

 

 

—

*: Weinreich J, Archid R, Bajaeifer K, Hack A, Königsrainer A, Schott TC. Growth and Chemosensitivity of Gastric Adenocarcinoma and Non-Malignant Cell Lines in Response to Novel Anti-Cancer Drug Combinations. Chemotherapy. 2014; 60(5-6):346-352. DOI: 10.1159/000438943. Epub 2015 Aug 29.